Objective: To observe the effect of renal artery denervation (RDN) on cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention (AMI-PCI).
Methods: This is a single-centre, prospective randomized controlled study. A total of 108 AMI-PCI patients were randomly assigned to the RDN group or the control group at 1:1 ratio. All patients received standardized drug therapy after PCI, and patients in the RDN group underwent additional RDN at 4 weeks after the PCI. The follow-up period was 6 months after RDN. Echocardiography-derived parameters, cardiopulmonary exercise testing (CPET) data, Holter electrocardiogram, heart rate variability (HRV) at baseline and at the 6 months-follow up were analyzed.
Results: Baseline indexes were similar between the two groups (all P > 0.05). After 6 months of follow-up, the echocardiography-derived left ventricular ejection fraction was significantly higher in the RDN group than those in the control group. Cardiopulmonary exercise test indicators VOMax, metabolic equivalents were significantly higher in the RDN group than in the control group. HRV analysis showed that standard deviation of the normal-to-normal R-R intervals, levels of square root of the mean squared difference of successive RR intervals were significantly higher in the RDN group than those in the control group.
Conclusions: RDN intervention after PCI in AMI patients is associated with improved cardiac function, improved exercise tolerance in AMI patients post PCI. The underlying mechanism of RDN induced beneficial effects may be related to the inhibition of sympathetic nerve activity and restoration of the sympathetic-vagal balance in these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362181 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2023.e17591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep learning model for low-dose CT late iodine enhancement imaging and extracellular volume quantification.
Eur Radiol
December 2024
Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objectives: To develop and validate deep learning (DL)-models that denoise late iodine enhancement (LIE) images and enable accurate extracellular volume (ECV) quantification.
Methods: This study retrospectively included patients with chest discomfort who underwent CT myocardial perfusion + CT angiography + LIE from two hospitals. Two DL models, residual dense network (RDN) and conditional generative adversarial network (cGAN), were developed and validated.
Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives.
J Am Heart Assoc
December 2024
Department of Cardiology West China Hospital, Sichuan University Chengdu China.
Renal denervation (RDN) is recognized as an adjunct therapy for hypertension management with a favorable and consistent blood pressure-lowering efficacy and safety profile. Alteration in medication burden is another noteworthy outcome of RDN for clinicians and patients. In this review, we summarized current clinical trials and patient perspectives, focusing on the use of antihypertensive medication (AHM) after RDN.
View Article and Find Full Text PDFPhysicians' perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society.
Hipertens Riesgo Vasc
December 2024
Hypertension Unit, ICBA, Buenos Aires, Argentina.
Introduction: This study investigates the perceptions and knowledge of specialized Argentine physicians regarding renal denervation (RDN) as a treatment for resistant hypertension (R-HT).
Method: A survey was conducted among 206 physicians, mainly cardiologists and internists, to assess their awareness and perceptions of RDN. Data were analyzed using descriptive statistics and Spearman's Rho correlation.
Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants.
Hypertension
January 2025
Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany (L.L., M.K., M.B., F.M.).
Background: Renal denervation lowers blood pressure (BP) in patients with uncontrolled hypertension. We conducted an unbiased genomic screen to identify genetic variants that may associate with BP response to renal denervation (RDN).
Methods: Patients (n=268) with uncontrolled resistant hypertension (baseline BP, 166±21/90±15 mm Hg) who underwent endovascular RDN using the Symplicity catheter (Medtronic, Inc, Santa Rosa, CA) were included.
Selecting Transfemoral Access or Upper Extremity Access for Renal Denervation Based on Vascular Morphology: Long-term Results.
J Clin Hypertens (Greenwich)
December 2024
Department of Cardiology, National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- - The study compared the long-term effectiveness and safety of renal denervation through transfemoral access (TFA) and upper extremity access (UEA) in patients with resistant hypertension, analyzing data from 85 patients treated at Fuwai Hospital from 2012 to 2019.
- - Results indicated that TFA had a shorter fluoroscopy time, while both groups had similar procedure times and contrast volumes, with no serious complications reported.
- - Follow-up data showed no significant differences in blood pressure changes, antihypertensive medication use, or renal function between TFA and UEA, though more adverse events were reported in the TFA group without significant difference.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!